SURUNKALI VIRUSLI GEPATITLI BEMORLAR ORASIDA GEPATOTSELLYULYAR KARSINOMANI ERTA ANIQLASH VA PROFILAKTIKASINING LABORATORIYA-DIAGNOSTIK MODELINI ILMIY ASOSLASH

Feruzakhon Abduvalieva; Farrux Karimjonov; Foziljon Rasulov

Mualliflar

Feruzakhon Abduvalieva PhD associate professor, Fergana medical institute of public health, Fergana, Uzbekistan ##default.groups.name.author##
Farrux Karimjonov Ferghana Medical Insititute of Public Health Department of Microbiology, virology and immunalogy, Uzbekistan ##default.groups.name.author##
Foziljon Rasulov Candidate of Medical Sciences, Associate Professor Head of the Department of Microbiology, Virology and Immunology Fergana Public Health Medical Institute ##default.groups.name.author##

Kalit so‘zlar:

surunkali virusli gepatit, gepatotsellyulyar karsinoma, gepatit B virusi, gepatit C virusi, alfa-fetoprotein

Abstrak

Gepatotsellyulyar karsinoma (GSK) jigar xavfli o‘smalarining eng ko‘p uchraydigan turi bo‘lib, ko‘p hollarda surunkali virusli gepatit B va C infeksiyalari fonida rivojlanadi. Kasallikning dastlabki bosqichlarda klinik belgilarsiz kechishi erta tashxis qo‘yishni murakkablashtiradi va davolash samaradorligini pasaytiradi. Mazkur maqolada surunkali virusli gepatitli bemorlarda gepatotsellyulyar karsinomani erta aniqlash va profilaktikasida laborator-diagnostik yondashuvlarning ahamiyati ilmiy adabiyotlar asosida tahlil qilindi. Alfa-fetoprotein, jigar fermentlari, virus yuklamasi va zamonaviy biomarkerlarning diagnostik imkoniyatlari baholanib, laborator ko‘rsatkichlarni klinik xavf omillari bilan uyg‘unlashtirish kasallikni erta aniqlash va yuqori xavf guruhidagi bemorlarni saralashda muhim ahamiyatga ega ekanligi ko‘rsatildi

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Havolalar

1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021.

2. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023.

3. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nature Reviews Clinical Oncology. 2023.

4. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021.

5. Musabaev E, Estes C, Sadirova S, Bakieva S, Brigida K, Dunn R, Kottilil S, Mathur P, Abutaleb A, Razavi-Shearer K, Anstiss T, Yusupaliev B, Razavi H. Viral hepatitis elimination challenges in low- and middle-income countries—Uzbekistan Hepatitis Elimination Program (UHEP). Liver International. 2023;43(4):773–784. doi:10.1111/liv.15514

6. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7:6. doi:10.1038/s41572-020-00240-3.

7. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965.

8. European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;69(1):182–236.